Tweet
I am preparing samples using the TruSeq DNA PCR Free library kit with UDI adaptors. The PI has requested that we perform Pippin Prep post adaptor ligation to remove adaptor contamination and target a narrow size distribution. Question is... because the protocol does not include denaturation prior to the final sequencing step, the non-homologous Y-shaped adaptors results in an atypical migration pattern on agarose gel and the Bioanalyzer results are substantially larger (750bp) than would be predicted (~350bp insert +adaptor range). Should I heat denature the samples prior to putting on Pippin Prep? Thoughts?
-
Last edited by vandykitty; 01-11-2018, 08:40 AM. -
I don't have any advice but want to know if you tried this and if it worked out.Originally posted by vandykitty View Post -
The PI did not want to advert from the protocol without assurance from Illumina or Sage Science that this would work, so unfortunately, no we did not try this. Sending the samples out for sequencing today.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment